CN116139202A - 一种增强人体摄吸氧气量的组合物及其制备方法 - Google Patents
一种增强人体摄吸氧气量的组合物及其制备方法 Download PDFInfo
- Publication number
- CN116139202A CN116139202A CN202211194633.1A CN202211194633A CN116139202A CN 116139202 A CN116139202 A CN 116139202A CN 202211194633 A CN202211194633 A CN 202211194633A CN 116139202 A CN116139202 A CN 116139202A
- Authority
- CN
- China
- Prior art keywords
- oxygen
- extract
- radix
- composition
- human body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000001301 oxygen Substances 0.000 title claims abstract description 180
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 180
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 173
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 99
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims abstract description 30
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 claims abstract description 30
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 25
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 25
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 24
- 150000001413 amino acids Chemical class 0.000 claims abstract description 22
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 20
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 20
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 20
- 235000008434 ginseng Nutrition 0.000 claims abstract description 20
- 210000003038 endothelium Anatomy 0.000 claims abstract description 19
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 16
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims abstract description 16
- 229940018333 calcium pyruvate Drugs 0.000 claims abstract description 16
- UZWMCCLZMHPPKW-UHFFFAOYSA-L calcium;2-oxopropanoate Chemical compound [Ca+2].CC(=O)C([O-])=O.CC(=O)C([O-])=O UZWMCCLZMHPPKW-UHFFFAOYSA-L 0.000 claims abstract description 16
- 229940108924 conjugated linoleic acid Drugs 0.000 claims abstract description 16
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 16
- 229960002666 1-octacosanol Drugs 0.000 claims abstract description 15
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 15
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 15
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 14
- 235000007240 daidzein Nutrition 0.000 claims abstract description 14
- 241000756943 Codonopsis Species 0.000 claims abstract description 12
- 241000222336 Ganoderma Species 0.000 claims abstract description 5
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 4
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 48
- 244000131316 Panax pseudoginseng Species 0.000 claims description 38
- 239000000463 material Substances 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 34
- 238000001556 precipitation Methods 0.000 claims description 27
- 241000112528 Ligusticum striatum Species 0.000 claims description 23
- 239000002994 raw material Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 235000001014 amino acid Nutrition 0.000 claims description 21
- 229940024606 amino acid Drugs 0.000 claims description 21
- 239000006228 supernatant Substances 0.000 claims description 21
- 240000008397 Ganoderma lucidum Species 0.000 claims description 20
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 20
- 240000004980 Rheum officinale Species 0.000 claims description 20
- 235000008081 Rheum officinale Nutrition 0.000 claims description 20
- 230000002829 reductive effect Effects 0.000 claims description 20
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 19
- 235000013305 food Nutrition 0.000 claims description 17
- 241000037740 Coptis chinensis Species 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 15
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 14
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 14
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 14
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 14
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 14
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 14
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 14
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 14
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 14
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 14
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 14
- 235000017803 cinnamon Nutrition 0.000 claims description 14
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 14
- 241000007126 Codonopsis pilosula Species 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 240000007164 Salvia officinalis Species 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 10
- 240000000249 Morus alba Species 0.000 claims description 9
- 235000008708 Morus alba Nutrition 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 238000004806 packaging method and process Methods 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 9
- 229930182490 saponin Natural products 0.000 claims description 9
- 150000007949 saponins Chemical class 0.000 claims description 9
- 241000282412 Homo Species 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 8
- 235000013824 polyphenols Nutrition 0.000 claims description 8
- 238000003860 storage Methods 0.000 claims description 8
- 108010024636 Glutathione Proteins 0.000 claims description 7
- 229960003180 glutathione Drugs 0.000 claims description 7
- 235000003969 glutathione Nutrition 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 241000287828 Gallus gallus Species 0.000 claims description 6
- 229930189092 Notoginsenoside Natural products 0.000 claims description 6
- 235000017276 Salvia Nutrition 0.000 claims description 6
- 235000020230 cinnamon extract Nutrition 0.000 claims description 6
- 238000007580 dry-mixing Methods 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 229930182494 ginsenoside Natural products 0.000 claims description 6
- 229940089161 ginsenoside Drugs 0.000 claims description 6
- 235000020717 hawthorn extract Nutrition 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 5
- 241000207929 Scutellaria Species 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 4
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000010404 Scutellaria baicalensis extract Substances 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 235000009697 arginine Nutrition 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 229960002173 citrulline Drugs 0.000 claims description 4
- 235000013477 citrulline Nutrition 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 235000018977 lysine Nutrition 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 229960003104 ornithine Drugs 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- 108090000145 Bacillolysin Proteins 0.000 claims description 3
- 108010059892 Cellulase Proteins 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 102000035092 Neutral proteases Human genes 0.000 claims description 3
- 108091005507 Neutral proteases Proteins 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 238000009455 aseptic packaging Methods 0.000 claims description 3
- 229940106157 cellulase Drugs 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 238000000643 oven drying Methods 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 235000013175 Crataegus laevigata Nutrition 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 235000013330 chicken meat Nutrition 0.000 claims description 2
- 240000000171 Crataegus monogyna Species 0.000 claims 3
- 230000001965 increasing effect Effects 0.000 abstract description 39
- 210000004072 lung Anatomy 0.000 abstract description 35
- 108010054147 Hemoglobins Proteins 0.000 abstract description 25
- 102000001554 Hemoglobins Human genes 0.000 abstract description 25
- 102000036675 Myoglobin Human genes 0.000 abstract description 20
- 108010062374 Myoglobin Proteins 0.000 abstract description 20
- 210000002345 respiratory system Anatomy 0.000 abstract description 20
- 230000017531 blood circulation Effects 0.000 abstract description 18
- 230000000241 respiratory effect Effects 0.000 abstract description 17
- 238000009423 ventilation Methods 0.000 abstract description 13
- 230000036961 partial effect Effects 0.000 abstract description 11
- 230000003213 activating effect Effects 0.000 abstract description 6
- 230000001502 supplementing effect Effects 0.000 abstract description 6
- 230000003915 cell function Effects 0.000 abstract description 2
- 241000208340 Araliaceae Species 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 description 115
- 230000007954 hypoxia Effects 0.000 description 84
- 210000004369 blood Anatomy 0.000 description 62
- 239000008280 blood Substances 0.000 description 62
- 210000004027 cell Anatomy 0.000 description 42
- 230000001737 promoting effect Effects 0.000 description 35
- 230000000694 effects Effects 0.000 description 29
- 210000002216 heart Anatomy 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 27
- 230000006870 function Effects 0.000 description 25
- 230000001976 improved effect Effects 0.000 description 23
- 230000002107 myocardial effect Effects 0.000 description 23
- 230000002633 protecting effect Effects 0.000 description 23
- 235000019197 fats Nutrition 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 20
- 210000004204 blood vessel Anatomy 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 19
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 210000004165 myocardium Anatomy 0.000 description 17
- 230000002685 pulmonary effect Effects 0.000 description 17
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 16
- 230000006378 damage Effects 0.000 description 16
- 150000003254 radicals Chemical class 0.000 description 16
- 230000029058 respiratory gaseous exchange Effects 0.000 description 16
- 230000003647 oxidation Effects 0.000 description 15
- 238000007254 oxidation reaction Methods 0.000 description 15
- 210000000056 organ Anatomy 0.000 description 14
- 230000004089 microcirculation Effects 0.000 description 13
- 230000001105 regulatory effect Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 13
- 206010002660 Anoxia Diseases 0.000 description 12
- 241000976983 Anoxia Species 0.000 description 12
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- 230000007953 anoxia Effects 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 230000002490 cerebral effect Effects 0.000 description 12
- 230000000916 dilatatory effect Effects 0.000 description 12
- 208000031225 myocardial ischemia Diseases 0.000 description 12
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241001092040 Crataegus Species 0.000 description 11
- 206010008118 cerebral infarction Diseases 0.000 description 11
- 206010016256 fatigue Diseases 0.000 description 11
- 230000004217 heart function Effects 0.000 description 11
- 206010037423 Pulmonary oedema Diseases 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- 208000005333 pulmonary edema Diseases 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 230000000747 cardiac effect Effects 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 206010036790 Productive cough Diseases 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004351 coronary vessel Anatomy 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 208000024794 sputum Diseases 0.000 description 8
- 210000003802 sputum Anatomy 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 210000000601 blood cell Anatomy 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 230000035764 nutrition Effects 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 7
- 201000006474 Brain Ischemia Diseases 0.000 description 6
- 206010048962 Brain oedema Diseases 0.000 description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 210000004958 brain cell Anatomy 0.000 description 6
- 208000006752 brain edema Diseases 0.000 description 6
- 210000000133 brain stem Anatomy 0.000 description 6
- 239000001569 carbon dioxide Substances 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 230000036284 oxygen consumption Effects 0.000 description 6
- 238000006213 oxygenation reaction Methods 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 230000004962 physiological condition Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000004202 respiratory function Effects 0.000 description 6
- 235000010288 sodium nitrite Nutrition 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 208000005374 Poisoning Diseases 0.000 description 5
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 5
- 206010038678 Respiratory depression Diseases 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000002929 anti-fatigue Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 150000003278 haem Chemical class 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 239000010813 municipal solid waste Substances 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 231100000572 poisoning Toxicity 0.000 description 5
- 230000000607 poisoning effect Effects 0.000 description 5
- 238000005086 pumping Methods 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 208000004852 Lung Injury Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229960002433 cysteine Drugs 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000008451 emotion Effects 0.000 description 4
- 235000011194 food seasoning agent Nutrition 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 230000004199 lung function Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 208000037891 myocardial injury Diseases 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 235000005412 red sage Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000035806 respiratory chain Effects 0.000 description 4
- 230000007958 sleep Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 3
- 206010069363 Traumatic lung injury Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000003617 erythrocyte membrane Anatomy 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 231100000515 lung injury Toxicity 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 210000003456 pulmonary alveoli Anatomy 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000035240 Disease Resistance Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- 206010044302 Tracheitis Diseases 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 208000009973 brain hypoxia - ischemia Diseases 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 230000030135 gastric motility Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000033116 oxidation-reduction process Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001012 protector Effects 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 230000036593 pulmonary vascular resistance Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000001034 respiratory center Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- WNXJCQJNRYHLIO-GEMLJDPKSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid;hydrate Chemical compound O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O WNXJCQJNRYHLIO-GEMLJDPKSA-N 0.000 description 1
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000099774 Cuscuta salina Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 244000265736 Nelumbo pentapetala Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003097 anti-respiratory effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- -1 oxygen radicals Chemical class 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000020874 response to hypoxia Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种增强人体摄吸氧气量的组合物及其制备方法,包括:辅酶Q10、共轭亚油酸、D‑核糖、二十八烷醇、L‑肉碱、丙酮酸钙、人参、党参、三七、灵芝、刺五加、川芎、桑白皮、黄芩、丹参、大豆甙元、黄连、大黄、肉桂、鸡内金、山楂、抗氧化剂、氨基酸。该组合物通过激活人体呼吸细胞功能和循环系统,增加肺通气量,提升肺内氧分压,增加血红蛋白和肌红蛋白的数量,提升血红蛋白和肌红蛋白的携氧能力,加快血液流动,增强人体依靠自身的呼吸系统从高原高山低压低氧环境和常压环境中摄取氧气量,随时、随地、不间断地持续补充氧气,人们就能在各种环境下生活和工作,为社会创造财富。
Description
技术领域
本发明涉及食品、保健品、药品技术领域,尤其涉及一种增强人体摄吸氧气量的组合物及其制备方法。
背景技术
氧是人体生理代谢的基本元素,是正常生命活动不可缺少的物质,缺氧广泛存在于人类的生活和工作中,尤其在高原、高山、高空或人体各器官生理性老化、剧烈的运动过程中以及呼吸和循环系统的某些疾病等不同情况下,都有可能出现缺氧的发生,当氧气供应量或利用率减少时,器官就会因缺氧而造成各种急性和慢性疾病,甚至死亡。中国地形多种多样,山地约占全国土地面积的33%,高原约占26%,高原、高山海拨高,气压低,氧气含量少,而居住在高原地区的人口约有1000万人,这部份人群长期处于低氧环境之中,高原、高山往往是军事、旅游、体育、科研、医学和经济的重要地区,常年有大量的人群居住和工作,自然环境常压缺氧和高原高山环境缺氧不同程度地影响着人们的身体健康需要关注,寻找解决办法,因此抗缺氧功能性研究显得尤为急迫。
高原高山环境性缺氧:在正常情况下,大气环境中的氧含量为20.9%,环境性缺氧是指在高原高山环境中大气的低气压,导致空气中的氧分压低,氧含量低于18%,人的肺内氧分压也随之降低,吸入相同体积的空气而吸入的氧减少,这样血红蛋白和肌红蛋白就不能被氧饱和,造成人的摄氧量不足,各部分组织、细胞就会出现相应的缺氧状态,长期在其中生活、工作,如不采取补充给氧等措施加以纠正,会造成人体的血管、心、脑、肺、肾、肝等组织器管的慢性损害,急性缺氧如果不能急时补氧,会造成肺水肿、脑水肿、心梗、脑梗,甚至死亡。
自然环境性缺氧:一是病理性缺氧:主要是呼吸系统的患者,由于从外界摄取氧气和通过血液循环输送氧气的能力下降,造成机体缺氧,当缺氧程度缓慢加重时,这种反射性兴奋呼吸中枢的作用迟钝,引起周期性呼吸、呼吸运动减弱,甚至呼吸停止,缺氧还可以损害血管内皮细胞,使肺毛细血管通透性增加,严重时导致肺水肿、脑水肿、心梗、脑梗,甚至死亡;二是生理性缺氧:随着年龄的增长,人体组织和器官生理性老化导致肺功能下降而引起的缺氧,持续的慢性缺氧容易发生心力衰竭,严重缺氧直接抑制呼吸中枢,使呼吸减弱或出现潮式呼吸,甚至呼吸停止;三是运动性缺氧:紧张的体力和脑力劳动会造成机体耗氧量增加,恶心、气喘、头晕眼花、虚脱无力,意识丧失,肌肉酸痛、心脑疾病等,严重的会有生命危险。
急性缺氧或长期慢性缺氧,人体呼吸系统及肺部容易出现炎性水种,导致痰液生成,而痰液在呼吸道及肺部组织细胞里会导致呼吸不畅,肺通气量下降肺内压力减小,而出现肺内氧分压降低,人体从自然界呼吸的氧气量就会减少而导致缺氧进一步加重,严重的会造成肺水肿、脑水肿、心梗、脑梗,甚至死亡;
研究与认识:高原高山缺氧、自然环境下的病理性缺氧、生理性缺氧和运动性缺氧的预防和冶疗形势非常严峻,临床救冶和预防研究目前没有实质性的进展,研究机构和普通人群认为:1.高原高山缺氧是大自然环境造成的缺陷,人力无可更改或氧气瓶吸氧或多种树;自然环境下的病理性缺氧、生理性缺氧和运动性缺氧是自然生理现象,人力可以更改或治疗或力所能及的多做有氧运动;2.缺乏有效的营养物质有针对性的不间断的持续补氧,3.抗缺氧研究主要是提高人体对缺氧的耐受力,让人体慢慢适应缺氧环境。
补氧现状:目前缺氧主要依靠医院吸氧、小型制氧机吸氧和外带氧气瓶吸氧等临时措施快速补氧,能暂时缓解因缺氧对人体造成的损害,现实中人们一旦缺氧或高原高山缺氧,作为应急措施到医院吸氧或小型制氧机吸氧和依靠随身携带的氧气瓶补氧,都有一定的局限性,人体缺氧时只能时断时续的吸点氧气,还做不到随时、随地持续性不间断地补氧;目前应对高原高山缺氧、常压环境下的生理性缺氧、病理性缺氧和运动性缺氧,只能应急,不能解决这部分人群因缺氧而出现的普遍性对氧的持续性需求,特别是高原高山缺氧,人们对氧的需求是随时、随地持续性不间断地补充氧气;现实中人们只能依靠自身的呼吸来应对缺氧,而靠人体自身从大气中呼吸氧气又达不到组织细胞对氧的需求,或吃点抗缺氧的药物,或者忍着,让人体慢慢地适应缺氧,任由缺氧对人体造成的各种不适和器管的慢慢损害;
市场和研发现状,而市场销售的抗缺氧红景天、高原安和复方党参片等保健品和药品,以及从目前提交的抗缺氧专利公开文件的配方中其药理研发重点主要集中在提高抗缺氧的耐受力和利用率,无增氧和补氧作用,而忽略了这些原料的相互协调,共同作用而达到的增强人体从大气环境中摄取氧气量的增氧、补氧功能,以及炎性水肿和痰液对呼吸系统及肺部组织细胞的影响和抗氧化作用对人体组织细胞和器管的保护作用。
综上所述,本项目研究认为:应对缺氧,应当从激活呼吸系统和循环系统、增强呼吸功能,增加肺通气量、提升肺内氧分压,增强人体从大气环境中摄取氧气量,提高血液系统的抗氧化能力,增加血红蛋白和肌红蛋白的数量,提升血红蛋白和肌红蛋白的携氧能力,降低血液粘度,增强血液的流动性,加快血液细胞运输氧气、贮存氧气和释放氧气,保护人体组织和器管免受缺氧损害的能力,是拮抗高原高山环境缺氧和常压环境的生理性缺氧、病理性缺氧和运动性缺氧的有效途径;因此,研发不受地域、随时、随地、不间断地持续的补氧药品、保健食品或食品具有广阔的市场前景。
发明内容
本发明的目的在于克服现有技术的不足,提供一种增强人体摄吸氧气量的组合物及其制备方法,该组合物解决了人们在高原高山低压低氧地区因空气中的氧分压下降导致肺内氧分压下降而出现的从空气中摄取的氧气不足,而出现的缺氧问题,以及人们在常压环境下因生理性、病理性和运动性导致呼吸和循环能力下降而出现的从空气中摄取的氧气不足,而出现的缺氧问题,减轻低压低氧环境和常压环境因缺氧对人体器官造成的损害,减缓生活和工作在高原高山地区以及常压环境的人们因缺氧所带来的生存压力,提高这部分人群的生活质量。
本发明的目的是通过以下技术方案来实现的:
一种增强人体摄吸氧气量的组合物,包括以下成分:
辅酶Q10 3~20kg、共轭亚油酸3~15kg、 D-核糖3~20kg、二十八烷醇0.1~1kg、L肉碱1~10kg、丙酮酸钙1~10kg、人参3~10kg、 党参3~15kg、三七1~10kg、灵芝3~15kg、刺五加1~10kg、川芎2~15kg、黄芩1~10kg、丹参2~25kg、大豆甙元1~10kg、桑白皮2~15kg、黄连0~15kg、大黄0~15kg、肉桂1~10kg、鸡内金1~10kg、山楂1~10kg、抗氧化剂3~15kg、氨基酸5~30kg。
进一步的,所述人参、党参、三七、灵芝、刺五加、川芎、黄芩、丹参、三七、桑白皮、大黄、黄连、肉桂、鸡内金、山楂的原料分别为人参皂苷、党参皂苷、三七皂苷、灵芝多糖、刺五加提取物、川芎提取物、黄芩提取物、丹参提取物、桑白皮提取物、大黄提取物、黄连提取物、肉桂提取物、山楂提取物、鸡内金提取物。
进一步的,所述抗氧化剂的原料为谷胱甘肽、维生素C和茶多酚按照质量比为1:1…1的混合而成的混合物。
进一步的,所述的氨基酸为赖氨酸、谷氨酸、天门冬氨酸、精氨酸、鸟氨酸、蛋氨酸、瓜氨酸、谷酰酸胺、酪氨酸、异亮氨酸、半胱氨酸、色氨酸和潘氨酸按照质量比为1:1…1混合而成的混合物。
进一步的,所述组合物用于食品、保健品、药品剂型中,还包括用于胶囊、片剂、冲剂和口服液。
进一步的,所述组合物中还包含调味剂。
进一步的,所述调味剂为苹果多酚、大豆低聚糖、甘露糖醇、海藻糖、丙氨酸的一种或多种。
进一步的,所述人参皂苷、党参皂苷、三七皂苷、灵芝多糖、刺五加提取物、川芎提取物、黄芩提取物、丹参提取物、桑白皮提取物、大黄提取物、黄连提取物、肉桂提取物、山楂提取物、鸡内金提取物的制备方法如下:
步骤1、准备原料:人参、党参、三七、灵芝、刺五加、川芎、黄芩、丹参、桑白皮、大黄、黄莲、肉桂、山楂、鸡内金;
步骤2、粉碎:将收集的中药材原料分品种经人工拣选,投入清洗并烘干至恒重,粉碎得到中药材细粉,过150~200目以上;
步骤3、提取:将中药材细粉输送至提取罐,加入纯净水,料水1:8、恒温85~95℃、时间1~2小时、3次,离心分离得上清液和中药材细粉渣,将上清液输入醇沉罐沉淀,将中药材细粉渣输送至提取罐;
在提取罐中加入纯净水,料水1:5,PH4.5~6.0、加入果胶酶和纤维素酶、恒温40~55℃、时间 2~3小时、2次,离心分离得上清液和中药材细粉渣,将上清液输入醇沉罐沉淀,将中药材细粉渣输送至提取罐;
在提取罐中加入纯净水,料水1:3、PH6.5~8.0加入中性蛋白酶、恒温25~35℃、2次、时间 2~3小时、离心分离得上清液,将上清液输入醇沉罐沉淀;
步骤4、纯化:将步骤3醇沉罐沉淀后的上清液减压浓缩至50%的体积,脱色后进行醇析、洗涤、真空干燥、溶解、超滤膜除杂、分离精制、真空干燥、得提取物成品以及皂苷、多糖成品待用。
一种增强人体摄吸氧气量的组合物的制备方法,所述制备方法如下:
S1、准备原料:按照制备增强人体从大气环境中摄取氧气量的组合物计,辅酶Q103~20kg、共轭亚油酸3~15kg、 D-核糖3~20kg、二十八烷醇0.1~1kg、L肉碱1~10kg、丙酮酸钙1~10kg、人参3~10kg、 党参3~15kg、三七1~10kg、灵芝3~15kg、刺五加1~10kg、川芎2~15kg、黄芩1~10kg、丹参2~25kg、大豆甙元1~10kg、桑白皮2~15kg、黄连0~15kg、大黄0~15kg、肉桂1~10kg、鸡内金1~10kg、山楂1~10kg、抗氧化剂3~15kg、氨基酸5~30kg;
将辅酶Q10、人参、党参、共轭亚油酸、灵芝、抗氧化剂干混均匀,此为A号料;将刺五加、丹参、川芎、黄芩、桑白皮、D-核糖、L-肉碱、二十八烷醇干混均匀,此为B号料;将大豆甙元、黄连、大黄、肉桂、鸡内金、山楂、丙酮酸钙、氨基酸、三七干混均匀,此为C号料;
S2、配料:将S1所得原料通过管道输送至配料罐,开启搅拌,依次加入A号料、B号料、C号料低速搅拌15~25min,待粉料在配料罐混合均匀,开启料网过滤,加工场地温度为:15~20℃;
S3、灭菌:将S2所得粉料灭菌后输送贮存罐;
S4、无菌分装:将S3所得粉料分装,无菌贮存罐粉料通过管道连接分装机,无菌分装得成品,装箱;
S5、检验。
本发明的有益效果:
本发明从众多的药食同源食材中精选出:辅酶Q10、共轭亚油酸、 D-核糖、二十八烷醇、L-肉碱、丙酮酸钙、人参、 党参、三七、灵芝、刺五加、川芎、桑白皮、黄芩、丹参、大豆甙元、黄连、大黄、肉桂、鸡内金、山楂、抗氧化剂、氨基酸等食药材,为人们提供了一种含有增强人体从大气环境中摄取氧气量的组合物;该组合物利用中药材的天然药效,与功能性激活细胞和循环系统原料、抗氧化原料、促进氧的摄取、增强氧的饱和度和运输利用等功能性原料各司其职又相互作用,充分发挥药效,增强人体从大气环境中摄取氧气量,随时、随地、持续性的补充氧气,应对高原高山缺氧、生理性缺氧、病理性缺氧和运动性缺氧对氧的需求;本配方食疗营养更加全面,剂量小、吸收快,见效快,药效长,安全、及时、方便、不受环境限制、随时、随地、不间断持续性地补氧,开创了人们在低压低氧环境和常压环境下依靠自身呼吸系统从大气环境中摄取氧气应对高原高山地区缺氧以及常压环境缺氧的补氧难题,在抗缺氧的研发中,为人们提出了开拓性的思路;
本发明的创新点:增强人体依靠自身的呼吸系统从高原高山低压低氧环境和常压的自然环境中摄取氧气量,随时、随地、不间断地为人体持续补充氧气,缓解高原高山低压低氧环境造成的人体缺氧和常压环境下造成的人体生理性缺氧、病理性缺氧和运动性缺氧,减轻因缺氧对人体器官造成的损害,减缓生活和工作在高原高山地区以及常压环境的人们因缺氧所带来的生存压力,提高人们的生存质量,人们就能在各种环境下生活和工作,为社会创造财富;一是激活人体呼吸细胞和呼吸功能,提升呼吸效率和强度,增强人体从大气环境中呼吸更多的氧气,同时将组织和细胞所产生的二氧化碳再通过循环系统到呼吸系统排出至体外;二是加强对呼吸道的清理和肺部的保护,改善呼吸气道的通畅,增加肺通气量,提升肺内氧分压,人体就能从自然环境中经呼吸系统不断地吸入到更多的氧气;三是不断增加血红蛋白和肌红蛋白的数量,增强血液中的血红蛋白和肌红蛋白与吸入的氧气融合,提升血细胞携氧带氧能力;四是保护血液中血红蛋白和肌红蛋白不受过氧化氢氧化和自由基氧化,提升血红蛋白和肌红蛋白的活力,保护人体组织细胞和器管不受过氧化氢氧化和自由基氧化,提高人体细胞、血液的携氧和输氧能力以及机体对氧的利用率;五是促进人体脂肪转化成能量,氧化分解体内脂肪营养心肌,变废为宝,提升心脏效能,提高心脏泵血能力,为人体血细胞携氧提供运行动力, 预防或治疗动脉硬化、脂类代谢失常、高血压、冠心病和血液循环碍障性疾病;六是活血化瘀,清除人体血管中的垃圾,增强血液的流动性,促进血液细胞快速运输氧气和释放氧气的能力,为心脑细胞和组织细胞提供氧气和能量,缓解或减轻因缺氧对人体器官造成的损害,预防因严重缺氧造成的脑水肿和肺水肿以及脑梗和心梗;七是促进食物的消化和吸收,为机体提供营养物质;八是降低血液中氮和二氧化碳的量,抑制乳酸生成,加快导致身体疲劳物质氨、氮和乳酸的排泄,维护身体的酸碱平衡,维护健康的肺功能,促进人体循环系统的正常运行;从而达到增强人体依靠自身的呼吸系统从低压低氧环境和常压的自然环境中摄取氧气量,随时、随地、不间断地,为生活和居住在高原高山地区的人们和常压环境下的生理性缺氧、病理性缺氧和运动性缺氧的人们持续地补充氧气;
本发明开创性的解决了缺氧从被动走向主动,即只能被动的应急的采取临时性吸氧和慢慢地去适应缺氧环境,到依靠自身的呼吸系统从低压低氧和常压的自然环境中主动的摄取氧气量,具有标本兼治的效果,且安全、及时、方便、不受环境限制、随时、随地、不间断持续性地补充氧气,产品以胶囊、片剂、冲剂、颗粒、口服液的方式生产,功能性原料易于采购,药食同源中药材易于加工成提取物,可进行工业化规模化生产;
1.以辅酶Q10、L-肉碱、川芎、刺五加、丹参、氨基酸的相互作用,激活人体呼吸细胞和呼吸功能,增强呼吸能力,提升呼吸效率和强度,人体就能从空气中摄取到更多的气体,肺通气量增强对人体的呼吸道至肺部(肺泡处的毛细血管)形成了压力,由气体通行的呼吸道和气体交换的肺功能得到了增强,肺内氧分压就得到了提升,人体从自然环境中经呼吸系统不断地吸入到更多的氧气,为心肌细胞和脑细胞提供充足的氧气,同时将组织和细胞所产生的二氧化碳再通过循环系统到呼吸系统排出至体外;
2.以辅酶Q10、D-核糖、氨基酸、刺五加、三七、川芎、黄芩、丹参、桑白皮、大黄的相互作用,增加人体毛细血管在低气压的防御能力,有效修复呼吸道,预防呼吸道感染,抑制炎性渗出和组织水肿,泻肺行水,促进分解肺部粘液蛋白(痰液)和痰液排出,治疗气管炎和其它呼吸系统疾病,对呼吸道的清理和肺部的保护,改善了呼吸气道的通畅,增加肺通气量,增强了通气压力,提升了肺内氧分压,人体就能从自然环境中经呼吸系统不断地吸入到更多的氧气;改善和提升人体肺通气量和肺部微循环,并减轻肺组织损伤,抑制缺氧后脑干FOS蛋白表达,它对呼吸抑制有拮抗作用,可保护脑干和神经细胞,延缓呼吸抑制的发展,促进免疫细胞的生成,增强人体的免疫力和抵抗力;
3.以人参、党参、灵芝多糖、丹参、大豆甙元、大黄、共轭亚油酸、氨基酸的相互作用,增加血红蛋白和肌红蛋白。改善骨髓造血能力,促进骨髓造血细胞的分裂,有助于血红素合成,使外周血中细胞、红细胞及血红蛋白含量增加,补充肌红蛋白,提升血液中血红素的含量,增强血液中的血红蛋白和肌红蛋白与氧融合饱和度,提升携氧带氧能力;
4.以辅酶Q10、谷胱甘肽、维生素C、茶多酚、半胱氨酸、二十八烷醇、共轭亚油酸、L-肉碱、丙酮酸钙、氨基酸的相互作用,保护组织和器官的正常运行。保护血液中血红蛋白和肌红蛋白不受过氧化氢氧化和自由基氧化,抑制亚硝酸盐,提升红细胞和血红蛋白以及肌红蛋白融合氧气的能力,从而使它持续正常发挥运输氧气的能力;保护人体组织细胞和器管不受过氧化氢氧化和自由基氧化,使细胞免受损害,维护人体组织细胞、器管的功能和正常运行,清除机体在缺氧环境下产生的自由基,增强对高山等应急能力的抵抗,提高人体细胞、血液的携氧和氧的输送能力以及机体对氧的利用率;
5.以D-核糖、共轭亚油酸、二十八烷醇、L-肉碱、丙酮酸钙、鸡内金、山楂、氨基酸的相互作用,氧化分解人体自身的脂肪营养心肌,增强心脏肌肉的效能,提高心肌泵血能力,提升心脏功能,为人体血细胞携氧提供运行动力,有利于保护心脏,既减少了人体的脂肪,降低了血脂,又为人体的心脏提供了力量的源泉,预防或治疗动脉硬化、脂类代谢失常、高血压、冠心病和血液循环碍障性疾病;促进食物的消化和吸收,为机体提供营养物质,促进糖原分解,为人体组织细胞供能;
6.氨基酸,管理体内废物,缓解压力,改善心情,帮助睡眠,在冠状动脉循环障碍缺氧时,能保护心肌免受低氧和缺血的损伤,降低血液中氮和二氧化碳的量,抑制乳酸生成,同时加速消除运动中积累的乳酸,加快导致身体疲劳物质氨、氮和乳酸的排泄,维护身体的酸碱平衡,维护健康的肺功能,调节情绪、预防焦虑和抑郁、帮助睡眠,促进人体循环系统的正常运行;
7.以辅酶Q10、D-核糖、共轭亚油酸、L-肉碱、丙酮酸钙、人参、党参、灵芝、刺五加、三七、川芎、黄芩、丹参、大豆甙元、黄莲、大黄、桑白皮、二十八烷醇、肉桂、山楂、抗氧化剂、氨基酸的相互作用,保持血管通畅,增强血液流动性,提高运氧和放氧能力,活血化瘀,清除人体血管的垃圾,抑止血小板聚集,降低血液粘度,抗血栓和抗凝血作用,改善微循环,扩张心脑血管和冠状动脉,使心脑血管阻力减轻,增强心脑血管和冠状动脉血流量,缓解因血液质改变而引起的呼吸困难,增强血液的流动性,快速运输氧和释放氧气能力,为心肌细胞和脑细胞提供氧气和能量,快速改善心脑缺血和缺氧,改善心脑机能,促进局部缺血组织和局部缺氧组织的恢复,对心肌缺血再灌注所引起的心肌损伤有保护作用,有效防止严重缺氧造成的人体脏器和大脑损伤,抑制因严重缺氧造成的肺水肿、脑水肿和抑制创伤性浮肿,阻止肺水肿的发展和冶疗肺水肿。
附图说明
图1是组合物对小鼠常压耐缺氧存活时间的影响表;
图2是组合物对小鼠急性脑缺血性缺氧存活时间的影响表;
图3是组合物对小鼠亚硝酸钠中毒存活时间的影响表;
图4是组合物对人体在高原环境下血氧饱和度的影响表。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述。显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。通常在此处附图中描述和示出的本发明实施例的组件可以以各种不同的配置来布置和设计。因此,以下对在附图中提供的本发明的实施例的详细描述并非旨在限制要求保护的本发明的范围,而是仅仅表示本发明的选定实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例一、本实施例公开了一种增强人体摄吸氧气量的组合物,包括以下成分:辅酶Q10 3~20kg、共轭亚油酸3~15kg、 D-核糖3~20kg、二十八烷醇0.1~1kg、L肉碱1~10kg、丙酮酸钙1~10kg、人参3~10kg、 党参3~15kg、三七1~10kg、灵芝3~15kg、刺五加1~10kg、川芎2~15kg、黄芩1~10kg、丹参2~25kg、大豆甙元1~10kg、桑白皮2~15kg、黄连0~15kg、大黄0~15kg、肉桂1~10kg、鸡内金1~10kg、山楂1~10kg、抗氧化剂3~15kg、氨基酸5~30kg。
本组合物原料的食疗价值:
辅酶Q10:激活呼吸细胞,是一种脂溶性醌类化合物,与线粒体内膜相结合,在呼吸链中是一个辅酶,起载体作用,在呼吸链中成为重要递氢体,细胞能量生成要素,是细胞代谢和细胞呼吸的激活剂,促进细胞产生能量的营养物质,具有改善细胞呼吸及保护线粒体的功能,能起到促进细胞呼吸作用,增加血液中带氧量,为心肌细胞和脑细胞提供充足的氧气和能量;抗氧化,具有强大的抗氧化作用,清除自由基,使细胞免受损害,保护细胞健康;畅通气道,可以有效修复受损的呼吸道,促进浓痰变稀和痰液排出,也是呼吸链的氧化还原成分改善呼吸功能,辅酶Q10的缺乏会导致呼吸功能的失常,出现痰多、呼吸不畅的现象,并有可能导致慢性呼吸道疾病如老慢支、哮喘、肺结核;保护心脏,预防心脑疾病,辅酶Q10促进心肌细胞的大量再生,是机体中要使用氧的所有细胞的必需成分,能显著提升心肌的带氧量,帮助心肌细胞产生能量,增强心肌泵血功能,延长心肌寿命,24小时保证充足的供血供氧,长期使用保持心脏的正常功能;报道称:辅酶Q10能增加心力衰竭的存活力达300%,超过75%的心脏病患者在服用辅酶Q10后,病情显著改善,大大的降低了猝死的风险。
共轭亚油酸:保护器管功能,是人和动物不可或缺的脂肪酸之一,又是人和动物无法合成的一种物质,能增强细胞膜的流动性,防止血管皮质增生,增强血管的舒张能力,维持器管微循环的正常功能和细胞的正常结构及功能;活血化瘀,有效发挥“血管清道夫”的作用,可清除血管中的垃圾,有效调节血液粘度,改善微循环,达到舒张血管,平稳血压的作用;提升携氧能力,有效促进人体蛋白的合成,显著增加人体的心肌肌红蛋白,骨骼肌肌红蛋白含量,肌红蛋白对氧的亲和力比血红蛋白高6倍,由于肌红蛋白的快速增加,显著增加人体肌红蛋白的数量,提高人体细胞、血液融氧、运氧和释放氧气的能力,有效防止严重缺氧造成的人体脏器和大脑损伤,显著抑制因严重缺氧造成的肺、脾水肿;抗氧化,增强人体抗氧化能力,调节血液胆固醇,增强细胞流动性,清除自由基,增强人体的抗氧化能力和免疫力;促进脂肪氧化分解,为人体提供能量,调节血液胆固醇和甘油三脂水平,防止动脉粥样硬化,对人体进行全面的良性调节作用,提高骨骼密度。
D-核糖:改善心肌营养,提升肺通气量,作为生物体内存在于所有细胞中的天然成分,与腺苷酸的形成和三磷酸腺苷(ATP)的再生有密切关系,是生命代谢最基本的能量来源之一,在心脏和骨骼代谢中起着关键作用,显著增强局部缺血后心肌能量及功能的恢复,进而改善心肌舒张功能,提升心衰患者的运动能力及肺通气量,改善心功能,促进局部缺血组织、局部缺氧组织的恢复,提高心脏局部缺血的耐受性,并提高心脏总体功能,用于冶疗心肌局部出血和改善心脏功能;保护缺血时的心脏,对因心脏缺血诱发的心律失常有保护作用,使原来一动就喘,经常心慌、胸闷、气虚的症状得以明显改善,生活质量大大提高;抗疲劳,还能增强肌体能量,缓解肌肉酸痛和慢性疲劳综合症和纤维肌。
二十八烷醇:增氧功能,改善心肌营养,减少心肌损伤的范围,增强对高山等应激能力的抵抗性,提高氧的输送能力和机体氧利用率,提高机体新陈代谢的比率,降低收缩期血压;改善心功能,抑制脂质过氧化,抗血栓、增强心肌耐缺血、缺氧的能力、改善心肌营养,减少心肌损伤的范围;抗疲劳,增强体力、耐力和精力,提高肌肉的力量,减轻肌肉的疼痛,减少肌肉摩擦,提高应激能力,提高反应敏锐性。
L-肉碱:氧化脂肪为能量,改变线粒体内呼吸酶的活性,提高人体的氧化功能,是游离的脂肪酸进入线粒体的载体,促进脂肪酸进入线粒体,使大量的脂肪参与氧化过程 ,能够减少糖原的消耗,提高脂肪的氧化速度,变成能量,进一步提高有氧能力,作为心肌的重要营养物质,可增加心肌能力,导致心脏血液输出量增加,故对心脏有明显的保护作用,抑制脂肪的吸收,在运动中可以促进身体内脂肪的燃烧来提供能量而达到减少脂肪堆积;清理血管垃圾,加速脂肪消耗,提高血液中的高密度脂蛋白水平,有助于清除体内的胆固醇,保护血管,降血压,加速脂肪消耗,降低血脂,减轻体重;抗氧化,还能清除自由基,保护细胞膜的稳定性;抗疲劳,抑制乳酸生成,同时加速消除运动中积累的乳酸,从而改善无氧运动的持续能力,促进尿素循环,提高运动能力,促进运动性疲劳的恢复。
丙酮酸钙:氧化脂肪为心肌供能,作用于心肌细胞线粒体,及时供给心肌活动所需能量,提高心肌泵血耐力,从而延长心脏寿命,对心脏有特殊的保护作用,可增强心脏肌肉的效能,提高心肌泵血耐力,减少心脏病或心脏局部缺血造成的损伤,促进心脏功能恢复,延长心脏寿命;抗氧化,丙酮酸钙具有吞噬体内自由基和抑制自由基的生成等显著效果;清理血管垃圾,降血脂、降低胆固醇与低密度胆固醇,有效预防高血脂及相关病症的发生,降低心脑血管动脉粥样硬化,内脏脂肪减少了,血管系统畅通了,可防止心脑细胞缺血性或缺氧性损伤,促进心脑功能恢复;减肥清脂,加速脂肪酸氧化,释放出大量的能量,控制脂肪生成,减少脂肪堆积,降低体重和体脂含量,降低甘油三酯,但不影响肌肉含量及运动能力。
人参:有滋补强壮、补气、安神、生津、止渴、明目、开心、益智功效。调节神经,调节中枢神经系统的作用,具有镇静大脑、调节神经,促进代谢,具有兴奋中枢神经,治疗神经衰弱;提升携氧能力,改善骨髓造血能力,促进骨髓造血细胞分裂,使外周血中细胞、红细胞及血红蛋白含量增加,提高血液中血红素的含量,增强血液携氧能力;保护心脏,快速改善心肌缺血和缺氧,改善心血管系统,治疗和预防冠心病,对心肌缺血再灌注所引起的心肌损伤有保护作用,调血压,抑制血小板凝集作用,恢复心脏功能;改善脑力,改善记忆与学习能力、促进DNA、RNA合成的作用;提高人的视力,及对暗环境适应能力;提升体力,具有提高体力、脑力劳动能力和抗疲劳作用,减缓体力衰退,提高工作效率,增耐力,恢复疲劳。
党参:补中益气,健脾益肺,益气生津、止渴,抗应激,提升携氧能力,增强骨髓的造血功能,又能增加红细胞和血红蛋白,增强血液携氧能力;调节神经,对神经系统有兴奋作用,镇静、抗惊厥,焦虑不安,心悸失眠健忘,;降压,扩张血管,改善微循环,调节血压;抗疲劳,缓解体倦无力,四肢乏力;改善脑力,促记忆,改善学习记忆障碍的作用和定向辨障碍;抗缺氧,增强机体抗病能力,提高对有害刺激的抵抗能力,具有抗常压缺氧、组织细胞缺氧、身体微循缺氧的作用。
三七:保护心脑系统,抑制血小板粘附和聚集,抗血栓和抗凝血作用,改善微循环,扩张脑血管,能使全脑或局部性脑缺血后再灌注水肿明显减轻,血脑屏障通透性改善,使脑血流量增加;提高缺氧的耐受力,在动脉压下降后,冠脉流量增加的同时,心肌氧摄取率和心肌耗氧量均显著下降或减少,甚至降压情况下,仍增加冠脉流量并降低心肌耗氧量,提高机体对缺氧的耐受力。抗感染,对急性炎症引起的毛细血管通透性升高、炎性渗出和组织水肿以及后期肉芽组织增生也均有抑制作用,抗动脉粥样硬化和提高机体免疫力。
灵芝:增氧功能,扩张冠状动脉,增加冠状动脉血流量,加强血液微循环,提高血液供氧能力,对脑缺氧、心肌缺氧有保护作用;保护胃黏膜,降低胃溃疡的发生率及减少胃黏膜出血,抑制应急性溃疡的形成;解毒保肝,减少化学药物 (毒物)对肝脏的损伤,加强肝脏代谢药物(毒物)的解毒功能;抗氧化,抑制或清除机体内的活性自由基,提高肝脏骨髓血液合成DNA、RNA蛋白能力,清除血中毒素,对受损的肝细胞起修复营养的作用,增强肝细胞功能,抵制或减少自由基对肝脏的伤害,增强肝细胞的解毒功能,减轻药物中毒性肝炎导致的化学性肝损伤,增强肝组织的抗病能力,同时,还能清除血液中的毒素,对受损的肝细胞起到修复作用。
刺五加:增氧,扩张血管,改善大脑血量,对血压具有双向调节作用,增加毛细血管在低气压的防御能力,提高人体的氧气吸收量,抗应激、增强适应性,抗菌、抗感染,耐缺氧,刺五加为有氧物质。
川芎:增加肺通气量,解除并防止血小板聚集,减少并防止红细胞壁的通透性,提高环磷酸腺苷含量,减少肺泡壁的通透性,抑制血栓素引起的肺血管痉挛,扩张肺血管,降低肺动脉压和肺血管阻力,从而改善肺通气量血流比例;抗肺损伤,扩张冠状动脉,增加冠状血流量,改善心肌流量及心肌营养,清除自由基,改善微循环和流态,改善心肌缺氧状况,扩张肺血管及肺毛细气管,降低肺动脉压和肺毛细血管内压,改善肺部微循环,冶疗肺水肿,减少动脉短路的开放及肺内分流,并减轻肺组织损伤;抗脑损伤,增加脑血管搏动性血容量,对慢性微循环障碍有明显调理作用,对血小板有解聚作用,减轻脑水肿;抗呼吸抑制,当脑干处于严重缺氧的状况下,脑干中的神经元功能会相应受到严重损害,从而容易引起呼吸抑制等症,川芎可以抑制缺氧后脑干FOS蛋白的表达,它对呼吸抑制有拮抗作用,可保护脑干和神经细胞,延缓呼吸抑制的发展,并延长生存期,具有抗氧化、清除氧由基、扩张血管和血栓形成等作用。
黄芩:抗脑损伤,影响血管的脆性与渗透性,改善血液循环,净化血液,降低血液黏稠度,对脑缺血再灌注损伤有明显的保护作用;抗肺损伤,防止低气压引起小白鼠肺出血,能使之减轻肺部损伤和延长存活日期,预防和治疗肺水肿。
丹参:保护心脏,扩张冠状动脉,增强心肌血氧供应,加强心肌收缩力,改善心脏功能,防止心肌急缺血和心肌梗死,加快微循环血流,不增加心肌耗氧量,促进毛细血管开放,减少能量消耗;抗脑损伤,扩张血管,抑制血小扳聚集,降低血粘度,对大脑中动脉血栓形成有预防作用,降低脑梗死范围,减轻脑水肿;改善心肺功能,改善行为障碍,提高纤溶酶活性,提高缺氧耐受力,促进组织的修复与再生作用,对呼吸系统疾病具有一定的治疗作用,在低氧状态下,可以对抗低氧所致肺动脉高压,降低肺血管阻力,并能改善由于低氧引起的心功能变化,使心排血量和每博输出量增加,动脉血氧分压升高。
大豆甙元:保护心脑系统,抑制血小扳聚集,扩张脑血管,改善脑循环,增加脑及冠状动脉的血流量,对缺氧心肌具有保护作用,抗心肌缺血,抗心律失常,稳定脑管功能,从而提高脑组织和细胞的供血和供氧,减少神经功能障碍的发生,对急性心肌缺血和脑缺血的保护作用;抗疲劳作用,增加血液对氧的供给,抑制心肌因缺氧而产生的乳酸,从而达到抗疲劳作用;降血压,改善血管微循环障碍,降低血压,抑制心率不齐,抑制毛细血管透过性的亢进;有效地抑制冠心病患者血清炎性因子的表达水平,从而发挥抗动脉粥样硬化,达到治疗冠心病的目的。
桑白皮:镇咳、祛痰、平喘、利尿,泻肺行水,抗炎,舒张心血管,免疫调节,预防和治疗肺水肿。
黄莲:清热燥湿,泻火解毒,高热神昏,抗炎,抗心肌缺血、抗脑缺血,提高对心脑及整体耐缺氧能力,能显著降低衰竭心脏的心肌和正常心肌耗氧量,对血小板聚集和释放的抑制作用,减慢心率及降低外周血管阻力。
大黄:泻热通肠,凉血解毒,逐瘀通经。能清除组织和血桨内的炎性介质,减轻组织器管损伤,可使肺组织的损伤减轻,防止病情恶化,降低毛细血管通透性,改善血管脆性,使血管收缩活动增加,能抑制红细胞抗体的产生,能增强巨噬细胞的吞噬功能,有利于对免疲细胞的调节作用。
肉桂:补火助阳、引火归元,散寒止痛、温通经脉。扩张外周血管,增加冠状动脉和脑血流量,使血压下降,改善心肌血液供应,抗血小板聚集,抗凝血。增强增强消化机能,排除肠道积气,具有保护心血管系统,调节中枢神经系统的功效,抗炎、抗菌、上热下寒。
山楂:健脾开胃、消食化滞、助消化,刺激胃液分泌,提高胃蛋白酶活性,促进蛋白质和脂肪消化,对胃肠道功能具有调节作用,治疗肉食积滞、胃脘胀满,降血脂,抗动脉粥样硬化,抗心肌缺血,增强心肌收缩力,增加心排血量的作用,降血压,活血化痰,抗氧化,加快胃的排空率,解决用餐后食物积聚胃内停滞不消化,促进食物的消化吸收,增强营养物质的供给,为人体提供能量。
鸡内金:消积滞,健脾胃,促进胃液分泌量、酸度及消化能力,促胃运动机能增强,治疗食积胀满,呕吐、反胃,疳积,消渴,加快胃的排空率,具有有较强的消食化积作用,解决用餐后食物积聚胃内停滞不消,促进食物的消化吸收,增强营养物质的供给,为人体提供能量。
抗氧化剂:
谷胱甘肽:有效去除人体自由基,提升人体免疫力,激活多种酶,从而促进糖、脂肪及蛋白质代谢,维持红细胞膜结构的稳定,保护血红蛋白不受过氧化氢氧化和自由基氧化,从而使它持续正常发挥运输氧的能力,红细胞中部分血红蛋白在过氧化氢等氧化剂的作用下,其中二价铁氧化为三价铁,使血红蛋白转变为高铁血红蛋白,从而失去了带氧能力,还原性谷胱甘肽既能直接与过氧化氢等氧化剂结合,生成水和氧化型谷胱甘肽,也能将高铁血红蛋白还原为血红蛋白;维持红细胞膜结构的稳定,消除氧化剂对红细胞膜结构的破坏作用。用于各种低氧血症,如急性贫血、成人呼吸窘迫症、败血症。能够减弱有毒物质的毒性,清除体内有毒物质;提高生物对于不良环境的抵抗能力。
维生素C:减低毛细血管脆性,增强机体对外界环境的抗应激能力和免疲力,保持血管的完整性,促进细胞代谢,帮助细胞排毒,抗体形成,促进铁的吸收,具有抗氧化和抗自由基的能力,保护血红蛋白不受过氧化氢氧化和自由基氧化,提升携氧能力。
茶多酚:抑制亚硝酸盐,排乳酸,醒脑提神。
氨基酸原料:
谷氨酸、天门冬氨酸、精氨酸和鸟氨酸:管理体内废物,优化力量和耐力,解氨毒,酸中毒,在冠状动脉循环障碍缺氧时,能保护心肌免受低氧和缺血的损伤,降低血液中氮和二氧化碳的量,增强肝脏功能,帮助睡眠和减轻疲劳;瓜氨酸:提高免疫系统功能,含有丰富的抗氧化剂吸收有害的自由基,维护健康的肺功能,降低压力和克服沮丧的情绪;蛋氨酸、赖氨酸:预防高血压和心脑血管疾病的发生,保护肺部免受进一步损害,为神经细胞的修复和正常活动提供能量,缺氧—rF(呼吸衰竭)疾病的脑保护剂,修复受损神经组织,影响呼吸链,为神经细节胞的修复和进行正常生理活动提供必要的能量来源,缓解焦虑情绪,改善睡眠;酪氨酸、色氨酸:有助于烟酸及血红素的合成,而血红素有载氧、贮氧、促进氧化还原、进行电子传递等重要生物学功能,缓解应激反应、预防精神疲劳的作用,可使缺氧者的认知能力和情绪得到改善,警觉性提高,烦躁感减少,调节情绪、预防焦虑,抑郁及慢性疲劳;潘氨酸:提高组织的氧气代谢率,缓解冠状动脉狭窄和气喘症状;谷酰酸胺:参与合成谷胱甘肽,减少酸性物质造成的运动能力的降低或疲劳,改善脑机能,谷酰酸胺保护大脑防止氨中毒,防止脑部疲劳,改善心情,增强智力;异亮氨酸:人体必需氨基酸,血红蛋白形成必须氨基酸,调节糖和能量水平,给人体提供能量,半胱氨酸:抗氧化剂,分解肺部粘液蛋白的作用,治疗气管炎和其它呼吸系统疾病,预防放射线损伤人体的作用。
本发明组合物的药理机制:食用本组合物后:能激活和增强人体呼吸功能,提升呼吸效率和强度,人体从自然界吸入的气体增多了,肺通气量增强对人体的呼吸道至肺部(肺泡处的毛细血管)形成了压力,由气体通行的呼吸道和气体交换的肺的功能得到了增强,肺内氧分压就得到了提升,这样人体从自然环境中经呼吸系统不断地吸入到更多的氧气,呼吸的氧气在肺循环中与肺泡中的毛细血管中的血红蛋白和肌红蛋白进行气体中的氧交换融合饱和,通过加快血液流动,血细胞携带的氧快速输送到人体的各类组织细胞中释放利用,同时将组织和细胞所产生的二氧化碳再通过循环系统到呼吸系统排出至体外,这样人体的循环系统正常运转了,组织细胞获得了机体运行的氧气,人体血液细胞和组织器管的功能得到了保护,生活和工作在高原高山低压低氧环境下的人们以及生活和工作在常压环境下生理性、病理性和运动性缺氧的人们获得了持续不断的氧气补充,缓解了高原高山地区和常压环境下生理性、病理性和运动性因缺氧带来的不适反应,减轻了低压低氧环境和常压环境下因缺氧对人体器官造成的损害,减缓生活和工作在高原高山地区以及常压环境的人们因缺氧所带来的生存压力。
本实施例进一步设置为:所述人参、党参、三七、灵芝、刺五加、川芎、黄芩、丹参、三七、桑白皮、大黄、黄连、肉桂、鸡内金、山楂的原料分别为人参皂苷、党参皂苷、三七皂苷、灵芝多糖、刺五加提取物、川芎提取物、黄芩提取物、丹参提取物、桑白皮提取物、大黄提取物、黄连提取物、肉桂提取物、山楂提取物、鸡内金提取物。
本实施例进一步设置为:所述抗氧化剂的原料为谷胱甘肽、维生素C和茶多酚按照质量比为1:1…1的混合而成的混合物。
本实施例进一步设置为:所述的氨基酸为赖氨酸、谷氨酸、天门冬氨酸、精氨酸、鸟氨酸、蛋氨酸、瓜氨酸、谷酰酸胺、酪氨酸、异亮氨酸、半胱氨酸、色氨酸和潘氨酸按照质量比为1:1…1混合而成的混合物。
本实施例进一步设置为:所述组合物用于食品、保健品、药品剂型中,还包括用于胶囊、片剂、冲剂和口服液中。
本实施例进一步设置为:所述组合物中还包含调味剂。
本实施例进一步设置为:所述调味剂为苹果多酚、大豆低聚糖、甘露糖醇、海藻糖、丙氨酸的一种或多种。
本实施例进一步设置为:所述人参皂苷、党参皂苷、三七皂苷、灵芝多糖、刺五加提取物、川芎提取物、黄芩提取物、丹参提取物、桑白皮提取物、大黄提取物、黄连提取物、肉桂提取物、山楂提取物、鸡内金提取物的制备方法如下:
步骤1、准备原料:人参、党参、三七、灵芝、刺五加、川芎、黄芩、丹参、桑白皮、大黄、黄莲、肉桂、山楂、鸡内金;
步骤2、粉碎:将收集的中药材原料分品种经人工拣选,投入清洗并烘干至恒重,粉碎得到中药材细粉,过150~200目以上;
步骤3、提取:将中药材细粉输送至提取罐,加入纯净水,料水1:8、恒温85~95℃、时间1~2小时、3次,离心分离得上清液和中药材细粉渣,将上清液输入醇沉罐沉淀,将中药材细粉渣输入提取罐;
在提取罐中加入纯净水,料水1:5,PH4.5~6.0、加入果胶酶和纤维素酶、恒温40~55℃、时间 2~3小时、2次,离心分离得上清液和中药材细粉渣,将上清液输入醇沉罐沉淀,将中药材细粉渣输入提取罐;
在提取罐中加入纯净水,料水1:3、PH6.5~8.0加入中性蛋白酶、恒温25~35℃、2次、时间 2~3小时、离心分离得上清液,将上清液输入醇沉罐沉淀;
步骤4、纯化:将步骤3醇沉罐沉淀后的上清液减压浓缩至50%的体积,脱色后进行醇析、洗涤、真空干燥、溶解、超滤膜除杂、分离精制、真空干燥、得提取物成品以及皂苷、多糖成品待用。
一种增强人体摄吸氧气量的组合物的制备方法,所述制备方法如下:
S1、准备原料:按照制备增强人体摄取氧气量的组合物计,辅酶Q10 3~20kg、共轭亚油酸3~15kg、 D-核糖3~20kg、二十八烷醇0.1~1kg、L肉碱1~10kg、丙酮酸钙1~10kg、人参3~10kg、 党参3~15kg、三七1~10kg、灵芝3~15kg、刺五加1~10kg、川芎2~15kg、黄芩1~10kg、丹参2~25kg、大豆甙元1~10kg、桑白皮2~15kg、黄连0~15kg、大黄0~15kg、肉桂1~10kg、鸡内金1~10kg、山楂1~10kg、抗氧化剂3~15kg、氨基酸5~30kg;
将辅酶Q10、人参、党参、共轭亚油酸、灵芝、抗氧化剂干混均匀,此为A号料;将刺五加、丹参、川芎、黄芩、桑白皮、D-核糖、L-肉碱、二十八烷醇干混均匀,此为B号料;将大豆甙元、黄连、大黄、肉桂、鸡内金、山楂、丙酮酸钙、氨基酸、三七干混均匀,此为C号料;
S2、配料:将S1所得原料通过管道输送至配料罐,开启搅拌,依次加入A号料、B号料、C号料低速搅拌15~25min,待粉料在配料罐混合均匀,开启料网过滤,加工场地温度为:15~20℃;
S3、灭菌:将S2所得粉料灭菌后输送贮存罐;
S4、无菌分装:将S3所得粉料分装,无菌贮存罐粉料通过管道连接分装机,无菌分装得成品,装箱;
S5、检验。
实施例二、本实施例与实施例一的区别之处在于:
本实施例中,在S4之前还具有调味和澄清步骤,所述调味具体为:将S2所得料粉输送至调味罐加入纯净水,加热至30~40℃,, 加入调味剂至溶解,低速搅拌至混合均匀,开启过滤器除去杂物。
所述澄清具体为:将S3所得料液冷却,冷却至0℃,恒温10-30min,开启过滤器除去杂物,输送至无菌贮存罐。上述步骤用于制备口服液。
一种增强人体摄吸氧气量的组合物的实验例:
1、试验项目:小鼠常压耐缺氧试验;急性脑缺血性缺氧试验;亚硝酸钠中毒试验;
1.1、昆明小鼠体重±5g的雌雄各半60只,随机分为2组,对照组、组合物组,每组10只小鼠,雌雄各半,对照组每天给予饲料,组合物组剂量按成年人65kg体重与小鼠体重进行折算,组合物与饲料加工成小颗粒混合物,每日上午给药一次,对照组、组合物组给予等量饲料,连续给药14天,在给药第14天测试;
1.2、小鼠常压耐缺氧试验;
1.3、耐缺氧存活时间测定:末次给药2h后,将小鼠放入装有5g钠石灰的200ml密封的广口瓶里,1只/每瓶,用凡士林封瓶口密封后,开始计时,以呼吸停止时间为指标,观察小鼠因缺氧而死亡的时间,每组小鼠平行进行测定;
1.4、实验结果,如图1所示,实验结论:组合物组小鼠常压耐缺氧存活时间比对照组增加了4.5min,延长了27.61%的时间,表明组合物组具体明显的耐缺氧能力。
2.1、急性脑缺血性缺氧试验;
2.2、于末次给予组合物2h后,各组小鼠自颈部逐只断头,立即按秒表记录小鼠断头后至张口喘气停止时间;
2.3、实验结果,如图2所示,实验结论:组合物组小鼠急性脑缺血性缺氧存活时间比对照组增加了3.7min,延长了23.72%,说明组合物组可明显增加小鼠急性脑缺血性缺氧存活时间。
3.1、亚硝酸钠中毒试验;
3.2、于末次给予小鼠组合物2h后,组合物组按成年人65kg体重与小鼠体重进行折算,腹腔注射亚硝酸钠,计时,观察小鼠存活时间并作好记录;
3.3、实验结果,如图3所示,实验结论:组合物对小鼠亚硝酸钠中毒存活时间比对照组增加了3.65min,延长小鼠存活时间增长了35.8%,表明组合物组可明显延长小鼠亚硝酸钠中毒存活时间。
4、试验项目:组合物对人体在高原环境下的摄取氧气量实验;
4.1、试验地点:拉萨市,海拨3650米,藏汉民族居民20人、藏汉各半、男女各半、年龄段(20-30岁、30-40岁、40-50岁、50-60岁、60-70岁)各2人,在拉萨市连续居住3个月以上;
4.2、试验工具:组合物、脉搏血氧仪;
4.3、基础数据组:藏民族组10人,汉民族组10人,连续14天分上午、下午定时采集血氧饱和度并记录,计算出藏汉民族组各10人的血氧饱和度平均数作为基础数据;
4.4、组合物组:采集基础数据的藏民族组10人,汉民族组10人,每人每天上午8h前食用组合物,3h后,连续14天分上午、下午定时采集血氧饱和度并记录,计算出藏汉民族组各10人的血氧饱和度平均试验数据;
4.5、实验结果,如图4所示,实验结论:组合物与基础数据相比,组合物藏民族组血氧饱和度增加了2.8,组合物汉民族组血氧饱和度增加了3.6,表明组合物能增强人体在高原地区摄取氧气量,具有从低压低氧环境中补充氧气的能力。
Claims (9)
1.一种增强人体摄吸氧气量的组合物,其特征在于,包括以下成分:
辅酶Q10 3~20kg、共轭亚油酸3~15kg、 D-核糖3~20kg、二十八烷醇0.1~1kg、L肉碱1~10kg、丙酮酸钙1~10kg、人参3~10kg、 党参3~15kg、三七1~10kg、灵芝3~15kg、刺五加1~10kg、川芎2~15kg、黄芩1~10kg、丹参2~25kg、大豆甙元1~10kg、桑白皮2~15kg、黄连0~15kg、大黄0~15kg、肉桂1~10kg、鸡内金1~10kg、山楂1~10kg、抗氧化剂3~15kg、氨基酸5~30kg。
2.根据权利要求1所述的一种增强人体摄吸氧气量的组合物,其特征在于:所述人参、党参、三七、灵芝、刺五加、川芎、黄芩、丹参、三七、桑白皮、大黄、黄连、肉桂、鸡内金、山楂的原料分别为人参皂苷、党参皂苷、三七皂苷、灵芝多糖、刺五加提取物、川芎提取物、黄芩提取物、丹参提取物、桑白皮提取物、大黄提取物、黄连提取物、肉桂提取物、山楂提取物、鸡内金提取物。
3.根据权利要求1所述的一种增强人体摄吸氧气量的组合物,其特征在于:所述抗氧化剂的原料为谷胱甘肽、维生素C和茶多酚按照质量比为1:1…1的混合而成的混合物。
4.根据权利要求1所述的一种增强人体摄吸氧气量的组合物,其特征在于:所述的氨基酸为赖氨酸、谷氨酸、天门冬氨酸、精氨酸、鸟氨酸、蛋氨酸、瓜氨酸、谷酰酸胺、酪氨酸、异亮氨酸、半胱氨酸、色氨酸和潘氨酸按照质量比为1:1…1混合而成的混合物。
5.根据权利要求1所述的一种增强人体摄吸氧气量的组合物,其特征在于:所述组合物用于食品、保健品、药品剂型中,还包括用于胶囊、片剂、冲剂和口服液。
6.根据权利要求1所述的一种增强人体摄吸氧气量的组合物,其特征在于:所述组合物中还包含调味剂。
7.根据权利要求6所述的一种增强人体摄吸氧气量的组合物,其特征在于:所述调味剂为苹果多酚、大豆低聚糖、甘露糖醇、海藻糖、丙氨酸的一种或多种。
8.根据权利要求2所述的一种增强人体摄吸氧气量的组合物,其特征在于:所述人参皂苷、党参皂苷、三七皂苷、灵芝多糖、刺五加提取物、川芎提取物、黄芩提取物、丹参提取物、桑白皮提取物、大黄提取物、黄连提取物、肉桂提取物、山楂提取物、鸡内金提取物的制备方法如下:
步骤1、准备原料:人参、党参、三七、灵芝、刺五加、川芎、黄芩、丹参、桑白皮、大黄、黄莲、肉桂、山楂、鸡内金;
步骤2、粉碎:将收集的中药材原料分品种经人工拣选,投入清洗并烘干至恒重,粉碎得到中药材细粉,过150~200目以上;
步骤3、提取:将中药材细粉输送至提取罐,加入纯净水,料水1:8、恒温85~95℃、时间1~2小时、3次,离心分离得上清液和中药材细粉渣,将上清液输入醇沉罐沉淀,将中药材细粉渣输入提取罐;
在提取罐中加入纯净水,料水1:5,PH4.5~6.0、加入果胶酶和纤维素酶、恒温40~55℃、时间 2~3小时、2次,离心分离得上清液和中药材细粉渣,将上清液输入醇沉罐沉淀,将中药材细粉渣输入提取罐;
在提取罐中加入纯净水,料水1:3、PH6.5~8.0加入中性蛋白酶、恒温25~35℃、2次、时间2~3小时、离心分离得上清液,将上清液输入醇沉罐沉淀;
步骤4、纯化:将步骤3醇沉罐沉淀后的上清液减压浓缩至50%的体积,脱色后进行醇析、洗涤、真空干燥、溶解、超滤膜除杂、分离精制、真空干燥、得提取物成品以及皂苷、多糖成品待用。
9.根据权利书要求1至8任意一项所述的一种增强人体摄吸氧气量的组合物的制备方法,其特征在于,所述制备方法如下:
S1、准备原料:按照制备增强人体摄取氧气量的组合物计,辅酶Q10 3~20kg、共轭亚油酸3~15kg、 D-核糖3~20kg、二十八烷醇0.1~1kg、L肉碱1~10kg、丙酮酸钙1~10kg、人参3~10kg、 党参3~15kg、三七1~10kg、灵芝3~15kg、刺五加1~10kg、川芎2~15kg、黄芩1~10kg、丹参2~25kg、大豆甙元1~10kg、桑白皮2~15kg、黄连0~15kg、大黄0~15kg、肉桂1~10kg、鸡内金1~10kg、山楂1~10kg、抗氧化剂3~15kg、氨基酸5~30kg;
将辅酶Q10、人参、党参、共轭亚油酸、灵芝、抗氧化剂干混均匀,此为A号料;将刺五加、丹参、川芎、黄芩、桑白皮、D-核糖、L-肉碱、二十八烷醇干混均匀,此为B号料;将大豆甙元、黄连、大黄、肉桂、鸡内金、山楂、丙酮酸钙、氨基酸、三七干混均匀,此为C号料;
S2、配料:将S1所得原料通过管道输送至配料罐,开启搅拌,依次加入A号料、B号料、C号料低速搅拌15~25min,待粉料在配料罐混合均匀,开启料网过滤,加工场地温度为:15~20℃;
S3、灭菌:将S2所得粉料灭菌后输送贮存罐;
S4、无菌分装:将S3所得粉料分装,无菌贮存罐粉料通过管道连接分装机,无菌分装得成品,装箱;
S5、检验。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211194633.1A CN116139202A (zh) | 2022-09-29 | 2022-09-29 | 一种增强人体摄吸氧气量的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211194633.1A CN116139202A (zh) | 2022-09-29 | 2022-09-29 | 一种增强人体摄吸氧气量的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116139202A true CN116139202A (zh) | 2023-05-23 |
Family
ID=86358882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211194633.1A Pending CN116139202A (zh) | 2022-09-29 | 2022-09-29 | 一种增强人体摄吸氧气量的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116139202A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1650901A (zh) * | 2004-02-02 | 2005-08-10 | 姜伟 | 从纯中药制剂中提取具有改善急性心肌供血不足抗缺氧抗心肌梗塞原料药的方法 |
CN1923228A (zh) * | 2005-08-31 | 2007-03-07 | 蔡军 | 三七提取物、丹参提取物和川芎嗪的药物组合物 |
CN103027944A (zh) * | 2011-10-07 | 2013-04-10 | 彭军 | 一种防治心脑血管疾病的药物组合物 |
CN103750143A (zh) * | 2014-01-21 | 2014-04-30 | 中国人民解放军第三军医大学 | 耐缺氧型抗疲劳能量组合物及其应用 |
CN104544400A (zh) * | 2014-12-31 | 2015-04-29 | 广东东阳光药业有限公司 | 一种含冬虫夏草提取物的复配保健饮料的制备方法 |
CN110664824A (zh) * | 2019-08-09 | 2020-01-10 | 北京佳博泰和健康科技有限公司 | 一种营养支持剂及其制备方法和用途 |
-
2022
- 2022-09-29 CN CN202211194633.1A patent/CN116139202A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1650901A (zh) * | 2004-02-02 | 2005-08-10 | 姜伟 | 从纯中药制剂中提取具有改善急性心肌供血不足抗缺氧抗心肌梗塞原料药的方法 |
CN1923228A (zh) * | 2005-08-31 | 2007-03-07 | 蔡军 | 三七提取物、丹参提取物和川芎嗪的药物组合物 |
CN103027944A (zh) * | 2011-10-07 | 2013-04-10 | 彭军 | 一种防治心脑血管疾病的药物组合物 |
CN103750143A (zh) * | 2014-01-21 | 2014-04-30 | 中国人民解放军第三军医大学 | 耐缺氧型抗疲劳能量组合物及其应用 |
CN104544400A (zh) * | 2014-12-31 | 2015-04-29 | 广东东阳光药业有限公司 | 一种含冬虫夏草提取物的复配保健饮料的制备方法 |
CN110664824A (zh) * | 2019-08-09 | 2020-01-10 | 北京佳博泰和健康科技有限公司 | 一种营养支持剂及其制备方法和用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109452521B (zh) | 一种辅助降尿酸肽固体饮料、制备方法及用途 | |
CN101574140A (zh) | 一种具有增强人体免疫功能和抗疲劳作用的饮品组合物 | |
CN106418545A (zh) | 一种营养均衡的功能性食品 | |
CN101253989B (zh) | 一种具有提高缺氧耐受力功能的保健食品及其制备方法 | |
US9707262B2 (en) | Composition with anoxia-tolerant and anti-fatigue effects and use thereof | |
CN106509887A (zh) | 一种抗疲劳保健组合物及其制备方法 | |
CN104274808A (zh) | 抗高原反应的中药组合物 | |
CN116509971A (zh) | 一种具有益智效果的中药组方、中药液和药物制剂 | |
CN104435648B (zh) | 一种食药两用的组合物及其用途和制备方法 | |
CN116139202A (zh) | 一种增强人体摄吸氧气量的组合物及其制备方法 | |
CN1060028C (zh) | 一种主要由谷物瓜菜果组成的健康食品 | |
CN111135235A (zh) | 一种预防和缓解急性酒精中毒或醉酒的组合物 | |
CN105998140B (zh) | 红景天含片 | |
CN101411493B (zh) | 一种防治疲劳型亚健康的凉茶及其制备方法 | |
CN107158299A (zh) | 一种具有增强学习记忆力功能的组合物及其制备方法 | |
CN112617196A (zh) | 一种抗缺氧、抗疲劳的食品、保健品或药物组合物及其制备方法和用途 | |
CN111418682A (zh) | 一种提升人体免疫功能的sod聚能香袋泡茶及其制备方法 | |
CN115554387A (zh) | 一种增强人体抗疲劳的组合物及其制备方法 | |
CN117256863B (zh) | 一种多维提高血红蛋白水平的血肽复合口服液及制备方法 | |
CN1736261A (zh) | 解酒保肝保健食品 | |
CN109730312A (zh) | 酵素组合物及其应用 | |
CN110025011A (zh) | 一种增强免疫力的麦冬人参含片 | |
CN114668830B (zh) | 一种解酒护肝组合物及其制备方法 | |
CN103404667A (zh) | 一种改善营养性贫血的食品养血茶冲剂 | |
CN108967757A (zh) | 一种红枣生姜浓浆生产工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |